10x Genomics 2025 Q3 Earnings Beats Revenue Estimates, Narrows Losses

10x Genomics (TXG) delivered mixed results in Q3 2025, surpassing revenue expectations while narrowing its net loss. The company reported $149 million in revenue, a 4.64% beat over Zacks’ consensus, and guided for 5% sequential growth in Q4. Despite a year-over-year revenue decline, the improved earnings and robust cash position underscore resilience amid sector headwinds.

Revenue

, , respectively. Consumables remained a stronghold, . Services revenue rose to $8.13 million, . The decline in total revenue (-1.7% YoY) reflected softer instrument demand but was offset by strong consumables performance.

Earnings/Net Income

, . While the loss remains a concern, the reduction signals progress in cost management and operational efficiency.

Post-Earnings Price Action Review

, reflecting renewed investor confidence. . , including the automation-compatible Flex assay, position the company to capitalize on long-term demand for single-cell analysis. However, . , .

CEO Commentary

, . While acknowledging macroeconomic challenges, . .

Guidance

, . . , , .

Additional News

, . , , . . Additionally, , , has gained traction, .